Fucoidan in lung cancer treatment: a comprehensive review of therapeutic applications and mechanisms
Lung cancer is a common malignancy in many countries and places a substantial mortality burden on public health systems worldwide. Despite recent advances in diagnosis and treatment, standard therapies often cause severe adverse effects and lead to drug resistance. These limitations highlight the need for safer and more effective treatment options. Fucoidan, a natural sulfated polysaccharide derived from marine brown algae, exhibits antitumor, antifibrotic, anti-inflammatory, and antioxidant activities, supporting its potential biomedical applications. Although interest in its biological activities has grown, research specifically addressing its therapeutic role in lung cancer remains limited. The molecular mechanisms underlying its effects on lung cancer cells are also incompletely understood. This review examines the pharmacological effects of fucoidan against lung cancer and evaluates its potential as an adjuvant therapeutic agent.
Authors
- Zhizhi Zhou (ORCID: https://orcid.org/0000-0003-0412-1128)
- Chao Zhou (ORCID: https://orcid.org/0000-0002-6205-2573)
- Haojie Sun (ORCID: https://orcid.org/0009-0001-1459-9339)
- Yulu Miao
- Wei Guo
- Mingying Liu (ORCID: https://orcid.org/0000-0001-9980-9704)
- Jing Xie
- Xingming Ma
Institutions
- Xihua University (CN)
- Huaihua University (CN)
- Army Medical University (CN)
- Sichuan University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Southwest Hospital (CN)
- State Key Laboratory of Oral Diseases (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Med-X
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1007/s44258-026-00100-x
- Primary Topic
- Seaweed-derived Bioactive Compounds
- Type
- article
- Field-Weighted Citation Impact
- 0.00